Russell Investments Group, Ltd. Affimed N.V. Transaction History

Russell Investments Group, Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 29, 2022	SELL	$2.27 - $4.86 $59,033 - $126,389	-26,006 Reduced 82.13%	5,657 $15,000
Q1 2022 May 05, 2022	SELL	$3.69 - $5.65 $325,838 - $498,911	-88,303 Reduced 73.61%	31,663 $138,000
Q4 2021 Jan 21, 2022	BUY	$5.37 - $7.07 $520,943 - $685,860	97,010 Added 422.59%	119,966 $662,000
Q3 2021 Nov 08, 2021	SELL	$5.54 - $7.51 $1.06 Million - $1.44 Million	-191,297 Reduced 89.29%	22,956 $141,000
Q2 2021 Aug 04, 2021	BUY	$7.78 - $11.4 $20,531 - $30,084	2,639 Added 1.25%	214,253 $1.82 Million
Q1 2021 May 10, 2021	BUY	$5.12 - $8.48 $223,872 - $370,788	43,725 Added 26.04%	211,614 $1.67 Million
Q4 2020 Feb 08, 2021	SELL	$3.16 - $7.03 $86,716 - $192,917	-27,442 Reduced 14.05%	167,889 $978,000
Q3 2020 Nov 09, 2020	BUY	$3.26 - $4.73 $156,864 - $227,598	48,118 Added 32.69%	195,331 $662,000
Q2 2020 Aug 05, 2020	BUY	$1.58 - $4.63 $5,457 - $15,992	3,454 Added 2.4%	147,213 $677,000
Q4 2019 Jan 29, 2020	SELL	$2.25 - $3.07 $478,505 - $652,893	-212,669 Reduced 59.67%	143,759 $394,000
Q3 2019 Nov 01, 2019	BUY	$2.67 - $3.65 $951,662 - $1.3 Million	356,428 New	356,428 $1.05 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.